GSK961081: Phase II data

In a 14-day, double-blind Phase II trial in 50 patients, once-daily inhaled doses of 400 and 1,200 µg of GSK9610810 improved FEV1 by 115 and 168 mL vs. placebo (p=0.013 and p<0.001, respectively). The...